Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.70 | N/A | -16.67% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.70 | N/A | -16.67% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their pipeline and emphasized the importance of upcoming milestones. They acknowledged the EPS shortfall but maintained a positive outlook on future developments.
Management highlighted ongoing progress in their clinical trials.
They expressed confidence in their long-term strategy despite the EPS miss.
Crinetics Pharmaceuticals reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by 4.27%, likely driven by positive sentiments around their ongoing clinical trials and management's confidence in their strategy. The lack of revenue data and guidance may leave some investors cautious, but the market reacted favorably to the overall tone of the call.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BIONTECH SE ADR
Aug 9, 2021